The AIDS Beacon

Beacon NewsFlashes – January 6, 2012

Generic Version Of Combivir Is Now Available – The generic version of Combivir (lamivudine/zidovudine), made by generic drug maker Teva Pharmaceuticals, is now available. Teva stated that it began shipping its generic form to pharmacies starting December 27.…

Beacon NewsFlashes – December 27, 2011

HHS Warns Against Three-Month Short-Course Tuberculosis Treatment For People On Antiretroviral Therapy – The Department of Health and Human Services (HHS) has warned that people with HIV who are on antiretroviral therapy should not take the new shortened, three-month regimen…

Beacon NewsFlashes – December 19, 2011

Gilead Applies For Approval For Truvada As An HIV-Prevention Drug – Gilead Sciences has applied for approval from the U.S. Food and Drug Administration (FDA) to market Truvada (emtricitabine/tenofovir) for the prevention of HIV infection. The application is…

Beacon NewsFlashes – December 13, 2011

Norvir Prescribing Information Updated To Include Risk Of Life-Threatening Skin Condition – The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for Norvir (ritonavir) to warn of the possibility of toxic epidermal necrolysis, a rare,…

Beacon NewsFlashes – December 5, 2011

President Obama Allocates An Additional $35 Million Toward ADAPs – In a speech on December 1, World AIDS Day, President Obama announced that the federal government will contribute an additional $35 million to state AIDS Drug Assistance Programs (ADAPs). The…

Beacon NewsFlashes – November 28, 2011

People With HIV Are At Increased Risk Of Six Cancers – Results from a recent study indicate that people with HIV are at an increased risk of developing Kaposi’s sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, melanoma, anal cancer, and liver cancer…

Beacon NewsFlashes – November 21, 2011

Foundation For AIDS Research Announces Additional $2.1 Million In Grants Towards AIDS Cure – The Foundation for AIDS Research (amfAR) has announced that it will distribute an additional $2.1 million in grants and fellowships to researchers working toward a cure…

Beacon NewFlashes – November 14, 2011

Merck To Collaborate With The Vaccine And Gene Therapy Institute On HIV Latency Research – U.S. pharmaceutical company Merck has entered into a three-year agreement with the Vaccine and Gene Therapy Institute of Florida to collaborate on research into HIV…

Beacon NewsFlashes – November 8, 2011

Isentress Prescribing Information Updated To Warn Of Severe Rash – The U.S. Food and Drug Administration (FDA) recently announced that the prescribing information for Isentress (raltegravir) has been updated to include a warning about the risk of a…

Estudio clínico en fase 3 demuestra que la pastilla “Quad” contra el VIH es tan eficaz como el Reyataz tomado con la Truvada

Los resultados de un estudio clínico en fase 3 aún en curso indican que la pastilla de combinación conocida informalmente como “Quad”, que se toma una vez al día, es tan eficaz como el Reyataz combinado con la Truvada en…